公开(公告)号：US07659263B2

公开(公告)日：2010-02-09

申请号：US11271136

申请日：2005-11-10

申请人： Ryo Mizojiri ,  Takahiro Oka ,  Kenta Aoki ,  Satoru Noji ,  Yoko Matsumoto ,  Toshihiro Sato ,  Izuru Ando ,  Yasushi Niwa

发明人： Ryo Mizojiri ,  Takahiro Oka ,  Kenta Aoki ,  Satoru Noji ,  Yoko Matsumoto ,  Toshihiro Sato ,  Izuru Ando ,  Yasushi Niwa

IPC分类号： A61P1/16 ,  A61P31/12 ,  A61P43/00 ,  A61K31/553 ,  A61K31/5517 ,  C07D498/12 ,  C07D267/02 ,  C07D495/14

CPC分类号： C07D498/14 ,  A61K31/5517 ,  A61K31/553 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention relates to a thienopyrrole compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound as an active ingredient. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

摘要翻译： 本发明涉及由下式[I]表示的噻吩并吡咯化合物，其中各符号如说明书中所定义，或其药学上可接受的盐，丙型肝炎病毒（HCV）聚合酶抑制剂和肝炎治疗剂 C含有该化合物作为活性成分。 本发明化合物基于HCV聚合酶抑制活性显示抗HCV活性，可用作预防或治疗丙型肝炎的药剂。

公开(公告)号：US20060167246A1

公开(公告)日：2006-07-27

申请号：US11271136

申请日：2005-11-10

申请人： Ryo Mizojiri ,  Takahiro Oka ,  Kenta Aoki ,  Satoru Noji ,  Yoko Matsumoto ,  Toshihiro Sato ,  Izuru Ando ,  Yasushi Niwa

发明人： Ryo Mizojiri ,  Takahiro Oka ,  Kenta Aoki ,  Satoru Noji ,  Yoko Matsumoto ,  Toshihiro Sato ,  Izuru Ando ,  Yasushi Niwa

IPC分类号： A61K31/553 ,  A61K31/551 ,  C07D498/14

CPC分类号： C07D498/14 ,  A61K31/5517 ,  A61K31/553 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention relates to a thienopyrrole compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound as an active ingredient. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

摘要翻译： 本发明涉及由下式[I]表示的噻吩并吡咯化合物，其中各符号如说明书中所定义，或其药学上可接受的盐，丙型肝炎病毒（HCV）聚合酶抑制剂和肝炎治疗剂 C含有该化合物作为活性成分。 本发明化合物基于HCV聚合酶抑制活性显示抗HCV活性，可用作预防或治疗丙型肝炎的药剂。

公开(公告)号：US20120020920A1

公开(公告)日：2012-01-26

申请号：US13034306

申请日：2011-02-24

申请人： Ryo Mizojiri ,  Shintaro Hirashima ,  Takahiro Oka ,  Kenta Aoki ,  Satoru Noji ,  Izuru Ando ,  Toshihiro Sato ,  Yasushi Niwa

发明人： Ryo Mizojiri ,  Shintaro Hirashima ,  Takahiro Oka ,  Kenta Aoki ,  Satoru Noji ,  Izuru Ando ,  Toshihiro Sato ,  Yasushi Niwa

IPC分类号： A61K38/21 ,  A61K31/4188 ,  A61K31/407 ,  A61P1/16 ,  A61K31/496 ,  A61K31/454 ,  A61K31/4545 ,  A61P31/14 ,  C07D495/04 ,  A61K31/5377

CPC分类号： C07D495/04

摘要： The present invention relates to a fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

摘要翻译： 本发明涉及由下式[I]表示的稠环化合物，其中各符号如说明书中所定义，或其药学上可接受的盐，丙型肝炎病毒（HCV）聚合酶抑制剂和治疗剂 含有该化合物的丙型肝炎。 本发明化合物基于HCV聚合酶抑制活性显示抗HCV活性，可用作预防或治疗丙型肝炎的药剂。

公开(公告)号：US20090036444A1

公开(公告)日：2009-02-05

申请号：US11436375

申请日：2006-05-18

申请人： Ryo Mizojiri ,  Shintaro Hirashima ,  Takahiro Oka ,  Kenta Aoki ,  Satoru Noji ,  Izuru Ando ,  Toshihiro Sato ,  Yasushi Niwa

发明人： Ryo Mizojiri ,  Shintaro Hirashima ,  Takahiro Oka ,  Kenta Aoki ,  Satoru Noji ,  Izuru Ando ,  Toshihiro Sato ,  Yasushi Niwa

IPC分类号： A61K31/5377 ,  C07D235/02 ,  A61K31/4188 ,  C07D495/02 ,  A61K31/496 ,  A61K31/454 ,  A61P31/12 ,  A61K31/4545 ,  C07D211/00 ,  C07D241/02 ,  A61K31/407 ,  C07D295/00

CPC分类号： C07D495/04

摘要： The present invention relates to a fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

摘要翻译： 本发明涉及由下式[I]表示的稠环化合物，其中每个符号如说明书中所定义，或其药学上可接受的盐，丙型肝炎病毒（HCV）聚合酶抑制剂和治疗剂 含有该化合物的丙型肝炎。 本发明化合物基于HCV聚合酶抑制活性显示抗HCV活性，可用作预防或治疗丙型肝炎的药剂。

公开(公告)号：US20070049593A1

公开(公告)日：2007-03-01

申请号：US11064319

申请日：2005-02-23

申请人： Takahiro Oka ,  Kazutaka Ikegashira ,  Shintaro Hirashima ,  Hiroshi Yamanaka ,  Satoru Noji ,  Yasushi Niwa ,  Yoko Matsumoto ,  Toshihiro Sato ,  Izuru Ando ,  Yukihiro Nomura

发明人： Takahiro Oka ,  Kazutaka Ikegashira ,  Shintaro Hirashima ,  Hiroshi Yamanaka ,  Satoru Noji ,  Yasushi Niwa ,  Yoko Matsumoto ,  Toshihiro Sato ,  Izuru Ando ,  Yukihiro Nomura

IPC分类号： C07D471/02 ,  A61K31/53 ,  A61K31/519 ,  A61K31/498 ,  A61K31/503 ,  A61K31/4745

CPC分类号： C07D513/04 ,  C07D487/04 ,  C07D487/14 ,  C07D498/04 ,  C07D498/14

摘要： The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

摘要翻译： 本发明涉及由下式[I]表示的四环稠合杂环化合物，其中各符号如说明书中所定义，或其药学上可接受的盐，丙型肝炎病毒（HCV）聚合酶抑制剂和治疗剂 含有该化合物的丙型肝炎。 本发明化合物基于HCV聚合酶抑制活性显示抗HCV活性，可用作预防或治疗丙型肝炎的药剂。

公开(公告)号：US07977331B1

公开(公告)日：2011-07-12

申请号：US11962622

申请日：2007-12-21

申请人： Takahiro Oka ,  Kazutaka Ikegashira ,  Shintaro Hirashima ,  Hiroshi Yamanaka ,  Satoru Noji ,  Yasushi Niwa ,  Yoko Matsumoto ,  Toshihiro Sato ,  Izuru Ando ,  Yukihiro Nomura

发明人： Takahiro Oka ,  Kazutaka Ikegashira ,  Shintaro Hirashima ,  Hiroshi Yamanaka ,  Satoru Noji ,  Yasushi Niwa ,  Yoko Matsumoto ,  Toshihiro Sato ,  Izuru Ando ,  Yukihiro Nomura

IPC分类号： A61K31/53 ,  A61K31/495 ,  A61K31/519 ,  A61K31/44 ,  A61K31/415 ,  A61K31/40 ,  C07D253/00 ,  C07D487/00 ,  C07D239/02 ,  C07D471/02 ,  C07D209/80

CPC分类号： C07D513/04 ,  C07D487/04 ,  C07D487/14 ,  C07D498/04 ,  C07D498/14

摘要： The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

摘要翻译： 本发明涉及由下式[I]表示的四环稠合杂环化合物，其中各符号如说明书中所定义，或其药学上可接受的盐，丙型肝炎病毒（HCV）聚合酶抑制剂和治疗剂 含有该化合物的丙型肝炎。 本发明化合物基于HCV聚合酶抑制活性显示抗HCV活性，可用作预防或治疗丙型肝炎的药剂。

公开(公告)号：US20120070409A1

公开(公告)日：2012-03-22

申请号：US13020621

申请日：2011-02-03

申请人： Takahiro Oka ,  Kazutaka Ikegashira ,  Shintaro Hirashima ,  Hiroshi Yamanaka ,  Satoru Noji ,  Yasushi Niwa ,  Yoko Matsumoto ,  Toshihiro Sato ,  Izuru Ando ,  Yukihiro Nomura

发明人： Takahiro Oka ,  Kazutaka Ikegashira ,  Shintaro Hirashima ,  Hiroshi Yamanaka ,  Satoru Noji ,  Yasushi Niwa ,  Yoko Matsumoto ,  Toshihiro Sato ,  Izuru Ando ,  Yukihiro Nomura

IPC分类号： A61K31/553 ,  C07D487/04 ,  C07D498/04 ,  C07D513/04 ,  A61K31/5365 ,  A61K31/55 ,  A61K31/407 ,  A61K31/542 ,  A61P1/16 ,  A61K38/21 ,  A61P31/14 ,  A61K31/554 ,  C07D498/14 ,  C07D471/14 ,  C07D471/04 ,  A61K31/4745 ,  C07D519/00 ,  A61K31/5517

CPC分类号： C07D513/04 ,  C07D487/04 ,  C07D487/14 ,  C07D498/04 ,  C07D498/14

摘要： The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

摘要翻译： 本发明涉及由下式[I]表示的四环稠合杂环化合物，其中各符号如说明书中所定义，或其药学上可接受的盐，丙型肝炎病毒（HCV）聚合酶抑制剂和治疗剂 含有该化合物的丙型肝炎。 本发明化合物基于HCV聚合酶抑制活性显示抗HCV活性，可用作预防或治疗丙型肝炎的药剂。

公开(公告)号：US08292992B2

公开(公告)日：2012-10-23

申请号：US12021666

申请日：2008-01-29

申请人： Toshihiro Sato ,  Manabu Oda ,  Koichiro Iwashita ,  Eiji Ochi ,  Susumu Okino ,  Takeo Shinoda ,  Tetsu Ushiku

发明人： Toshihiro Sato ,  Manabu Oda ,  Koichiro Iwashita ,  Eiji Ochi ,  Susumu Okino ,  Takeo Shinoda ,  Tetsu Ushiku

IPC分类号： B01D47/00

CPC分类号： B01D53/18 ,  B01D45/08 ,  B01D53/504 ,  B01D2257/302

摘要： A flue gas desulfurization apparatus includes an absorption tower that absorbs sulfur oxide in a flue gas, and drift suppression members that are arranged near a bend portion of a purified gas exhaust passage arranged at an outlet portion of the absorption tower, the drift suppression members serving to collect mist particles.

摘要翻译： 烟道气脱硫装置包括：吸收烟道气中的硫氧化物的吸收塔;配置在吸收塔出口部的净化气体排出通道的弯曲部附近的漂移抑制部件， 收集雾粒。

公开(公告)号：US08274218B1

公开(公告)日：2012-09-25

申请号：US13472863

申请日：2012-05-16

申请人： Masaya Adachi ,  Toshihiro Sato ,  Naoki Tokuda

发明人： Masaya Adachi ,  Toshihiro Sato ,  Naoki Tokuda

IPC分类号： H01J1/62

CPC分类号： H01L51/5262 ,  H01L27/3211 ,  H01L27/3244 ,  H01L27/3248 ,  H01L2251/5315 ,  H01L2251/558

摘要： A color light emitting display includes light-emitting devices constituting a plurality of red, green and blue pixels disposed in a matrix form on a substrate, said light-emitting display takes out light from a side of said light-emitting devices opposite to said substrate on which said light-emitting devices are formed, and wherein when a wavelength of the light having an interference intensity of which with respect to the light emitted from an emissive layer constituting said light-emitting device becomes a maximum value at 0 degree of a viewing angle is λimax, and a wavelength of the light becomes a maximum in a light intensity of the light emitted from said emissive layer is λemax, a relationship of λemax−50 nm≦λimax

摘要翻译： 彩色发光显示器包括构成以矩阵形式设置在基板上的多个红色，绿色和蓝色像素的发光器件，所述发光显示器从与所述基板相对的所述发光元件的一侧取出光 其上形成有所述发光装置，并且其中当相对于构成所述发光装置的发光层发射的光的干涉强度的光的波长在0度时成为最大值 角度为λimax，并且从所述发射层发射的光的光强度中的光的波长变为最大值为λemax，满足λemax-50nm＆lt; lE;λimax<λemax的关系。

公开(公告)号：US20120168970A1

公开(公告)日：2012-07-05

申请号：US13496354

申请日：2010-09-13

申请人： Toshihiro Sato ,  Masakazu Kawata ,  Masahiro Yoneyama ,  Toyosei Takahashi ,  Hirohisa Dejima ,  Fumihiro Shiraishi

发明人： Toshihiro Sato ,  Masakazu Kawata ,  Masahiro Yoneyama ,  Toyosei Takahashi ,  Hirohisa Dejima ,  Fumihiro Shiraishi

IPC分类号： H01L23/544 ,  H01L23/12 ,  B32B7/02 ,  H01L21/50

CPC分类号： H01L24/29 ,  H01L24/13 ,  H01L24/32 ,  H01L24/83 ,  H01L24/94 ,  H01L2224/29 ,  H01L2224/29101 ,  H01L2224/2919 ,  H01L2224/2929 ,  H01L2224/29386 ,  H01L2224/29388 ,  H01L2224/83 ,  H01L2924/00013 ,  H01L2924/01005 ,  H01L2924/01006 ,  H01L2924/01012 ,  H01L2924/01013 ,  H01L2924/01019 ,  H01L2924/0102 ,  H01L2924/01033 ,  H01L2924/01052 ,  H01L2924/01059 ,  H01L2924/01074 ,  H01L2924/014 ,  H01L2924/0665 ,  H01L2924/15788 ,  H01L2924/181 ,  Y10T428/2495 ,  H01L2924/00 ,  H01L2924/3512 ,  H01L2924/00012 ,  H01L2924/05432 ,  H01L2924/00014 ,  H01L2924/05442 ,  H01L2224/29099 ,  H01L2224/29199 ,  H01L2224/29299

摘要： A method of manufacturing a semiconductor wafer bonding product according to the present invention includes: a step of preparing a spacer formation film including a support base having a sheet-like shape and a spacer formation layer provided on the support base and having photosensitivity; a step of attaching the spacer formation layer to a semiconductor wafer having one surface from a side of the one surface; a step of forming a spacer by subjecting exposure and development to the spacer formation layer to be patterned and removing the support base; a step of bonding a transparent substrate to a region of the spacer, with which the removed support base made contact, so as to be included within the region. This makes it possible to manufacture a semiconductor wafer bonding product in which the semiconductor wafer and the transparent substrate are bonded together through the spacer uniformly and reliably.

摘要翻译： 根据本发明的制造半导体晶片接合产品的方法包括：制备包括具有片状形状的支撑基底和设置在支撑基底上并具有光敏性的间隔物形成层的间隔物形成膜的步骤; 将间隔物形成层从一个表面的一侧附着到具有一个表面的半导体晶片的步骤; 通过对间隔物形成层进行曝光和显影以形成图案化并去除支撑基底来形成间隔物的步骤; 将透明基板粘合到被移除的支撑基底与之接触的间隔件的区域中以便包括在该区域内的步骤。 这使得可以制造半导体晶片接合产品，其中半导体晶片和透明基板通过间隔件均匀可靠地结合在一起。